Role of the EpCAM (CD326) in prostate cancer metastasis and progression

Ni, Jie, Cozzi, Paul J., Duan, Wei, Shigdar, Sarah, Graham, Peter H., John, Kearsley H. and Li, Yong 2012, Role of the EpCAM (CD326) in prostate cancer metastasis and progression, Cancer metastasis reviews, vol. 31, no. 3-4, pp. 779-791.

Attached Files
Name Description MIMEType Size Downloads

Title Role of the EpCAM (CD326) in prostate cancer metastasis and progression
Author(s) Ni, Jie
Cozzi, Paul J.
Duan, Wei
Shigdar, Sarah
Graham, Peter H.
John, Kearsley H.
Li, Yong
Journal name Cancer metastasis reviews
Volume number 31
Issue number 3-4
Start page 779
End page 791
Total pages 13
Publisher Springer New York LLC
Place of publication New York, N. Y.
Publication date 2012-12
ISSN 0167-7659
1573-7233
Keyword(s) EpCAM
prostate cancer
immunotherapy
prognosis
circulating tumour cells
targeted cancer therapy
Summary Despite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a transmembrane glycoprotein that is highly expressed in rapidly proliferating carcinomas and plays an important role in the prevention of cell–cell adhesion, cell signalling, migration, proliferation and differentiation. Stably and highly expressed EpCAM has been found in primary CaP tissues, effusions and CaP metastases, making it an ideal candidate of tumour-associated antigen to detect metastasis of CaP cells in the circulation as well as a promising therapeutic target to control metastatic CRPC disease. In this review, we discuss the implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP. We also summarize EpCAM expression in human CaP and EpCAM-mediated signalling pathways in cancer metastasis. Finally, emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications of EpCAM for targeted strategies in future CaP therapy will be explored.
Language eng
Field of Research 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
Socio Economic Objective 920101 Blood Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Persistent URL http://hdl.handle.net/10536/DRO/DU:30050539

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 24 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 12 Feb 2013, 12:37:35 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.